Answers are grounded in this paper and cite their sources.
Purpose of review Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) is a rare but clinically important lymphoma subtype characterized by a distinct pattern of relapse, particularly involving the central nervous system (CNS) and contralateral testis. This review summarizes recent advances in the biology and management of PT-DLBCL, with a focus on developments from the past 18 months. Recent findings Recent genomic, transcriptomic and immune profiling studies have demonstrated marked biological heterogeneity within PT-DLBCL, extending beyond its predominant MCD/C5 molecular background. Distinct genomic subtypes, transcriptional programmes and immune microenvironmental features have been identified, including mechanisms of immune escape mediated by impaired antigen presentation. Clinically, CNS relapse remains a major challenge. Although CNS prophylaxis, including high-dose methotrexate, has been incorporated into standard practice, recent retrospective analyses have questioned its ability to significantly reduce CNS relapse risk. Summary PT-DLBCL is evolving from a disease defined primarily by anatomical site towards one increasingly informed by molecular and immune biology. These advances provide a rationale for future biology-driven approaches, including therapies targeting B-cell receptor signalling and immune-based strategies. However, prospective collaborative studies incorporating genomic profiling, immune characterization and molecular monitoring will be required to translate these insights into improved patient outcomes.
No takes yet. Share an insight, caveat, or question.
Seth et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: